Saqib Baig, MD
Pulmonary Disease · Philadelphia, PANPI 1619108834
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,602 of the $2,361 with a category attached, or 67.9%. Regeneron Healthcare Solutions, Inc. accounts for 67.9% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $1,669 and has fallen 75.5% since, to $409 in 2025.
Across 19 payments — averaging $124.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$2K
- Insmed, Inc.$471
- GSK$119
- Verona Pharma, Inc.$56
- Amgen$45
- Sanofi$30
- plus $38 from 2 others
Across 4 payments — averaging $52.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$209
What the payments were for
- Consulting fees$1,60268%
- Food & beverage$75932%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 2 | $1,602 |
| Insmed, Inc. | 5 | $471 |
| GSK | 6 | $119 |
| Verona Pharma, Inc. | 1 | $56 |
| Amgen | 2 | $45 |
| Sanofi | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| AstraZeneca | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,361 in reported general payments places this provider in the 60th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 18 | $274,813 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 170 | $156,257 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 147 | $88,257 |
| NucalaMepolizumab | 22 | $77,599 |
| FasenraBenralizumab | 12 | $69,480 |
| Fasenra PenBenralizumab | 11 | $63,690 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $29,744 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $24,469 |
| Incruse ElliptaUmeclidinium Bromide | 37 | $21,501 |
| Spiriva RespimatTiotropium Bromide | 27 | $19,124 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 27 | $13,515 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $11,888 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 262 | $10,123 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $8,908 |
| Spiriva HandihalerTiotropium Bromide | 12 | $8,626 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta, Incruse Ellipta | $119 | $373,357431 claims |
| Insmed, Inc.Arikayce | $471 | $274,81318 claims |
| AstraZenecaFasenra, Breztri Aerosphere, Bevespi Aerosphere, Symbicort | $16 | $116,37297 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$657K
- Parth RaliPhiladelphia$314K
- Steven GellerPhiladelphia$274K
- Christopher ManleyPhiladelphia$262K
- Jeffrey EdelsonPhiladelphia$233K
- Benjamin WindPhiladelphia$168K
- Boyd HehnPhiladelphia$157K
- Gary AaronsonPhiladelphia$122K
- Friedrich KueppersPhiladelphia$100K
- Philip SilkoffPhiladelphia$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.